Studies highlight existing BP meds

All hail ACE inhibitors and ACE add-ons. Three new studies put the drugs in the spotlight today: One showed that treatment with an ACE inhibitor was as effective at reducing deaths, heart attacks, and stroke in high-risk patients as was a newer, more expensive angiotensin-receptor blocker, or ARB drug. The study of more than 17,000 patients with coronary artery disease or diabetes found no major differences between those treated with Altace/ramipril, an ACE inhibitor, and those given Micardis/telmisartan, an ARB. The latter drugs tend to cost about 20 percent more, researchers said, so using an ACE inhibitor could save money.

Another study showed that an ACE inhibitor combined with a calcium channel blocker--in this case benazepril and amlodipine--outperformed an ACE inhibitor coupled with a diuretic. The calcium-channel blocker group had 15 percent fewer heart-related problems or strokes. This study was paid for by Novartis, which makes Lotrel (the benazepril/amlodipine combo), but all the meds are available individually in generic form.

And a third study showed that an ACE inhibitor and diuretic outperformed an ACE inhibitor alone, cutting fatal strokes by 39 percent and deaths from any cause by 21 percent--and this in patients in their 80s.

- get the ACE-CCB press release from the University of Michigan
- read about the ACE/ARB study in US News
- check out the Associated Press article

Related Articles:
Newer BP drugs no better than diuretics. Report
Heresy: Do we need cholesterol meds? Report
Merck, Schering defend embattled Vytorin. Report
PKG key to controlling blood pressure. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.